XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-based compensation
12 Months Ended
Jul. 01, 2023
Stock-based compensation  
Stock-based compensation

12. Stock-based compensation

The Company measures all stock-based payments at fair value and recognizes related expense within selling, general and administrative expenses in the consolidated statements of operations over the requisite service period (generally the vesting period). During fiscal 2023, 2022, and 2021, the Company recorded stock-based compensation expense of $38.8 million, $36.7 million, and $29.3 million, respectively, for all forms of stock-based compensation awards.

Stock plan

At July 1, 2023, the Company had 7.1 million shares of common stock reserved for stock-based payments, which consisted of 1.2 million shares for unvested or unexercised stock options, 4.6 million shares available for stock-based awards under plans approved by shareholders, and 1.4 million shares for restricted stock units and performance share units granted but not yet vested.

Stock options

Service based stock option grants have a contractual life of ten years, vest in 25% increments on each anniversary of the grant date, commencing with the first anniversary, and require an exercise price of 100% of the fair market value of common stock at the date of grant. Stock-based compensation expense associated with all stock options during fiscal 2023, 2022, and 2021, was $1.0 million, $3.6 million, and $0.4 million, respectively.

There were no stock options granted in fiscal 2023 and the unamortized stock-based compensation associated with unvested options was not material as of July 1, 2023.

Restricted stock units

Delivery of restricted stock units, and the associated compensation expense, is recognized over the vesting period and is generally subject to the employee’s continued service to the Company, except for employees who are retirement eligible under the terms of the restricted stock units. As of July 1, 2023, 1.2 million shares previously awarded have not yet vested. Stock-based compensation expense associated with restricted stock units was $30.5 million, $29.5 million, and $27.5 million for fiscal years 2023, 2022, and 2021, respectively.

The following is a summary of the changes in non-vested restricted stock units during fiscal 2023:

Weighted

 

Average

 

Grant-Date

 

    

Shares

    

Fair Value

 

Non-vested restricted stock units at July 2, 2022

 

1,313,182

$

32.92

Granted

 

802,424

 

41.67

Vested

 

(819,921)

 

34.94

Forfeited

 

(81,565)

35.95

Non-vested restricted stock units at July 1, 2023

 

1,214,120

$

37.14

As of July 1, 2023, there was $20.1 million of total unrecognized compensation expense related to non-vested restricted stock units, which is expected to be recognized over a weighted-average period of 2.1 years. The total fair value of restricted stock units vested during fiscal 2023, 2022, and 2021, was $28.6 million, $26.6 million, and $25.8 million, respectively.

Performance share units

Certain eligible employees, including Avnet’s executive officers, may receive a portion of their long-term stock-based compensation through the performance share program. Through grants of performance share units, this program provides for the vesting of underlying shares of Avnet’s common stock at the end of the third year performance period, based on the Company achieving certain performance goals that the Compensation Committee of the Board of Directors establishes for a three year period.

During fiscal 2023, the Company granted 0.2 million performance share units. During fiscal 2022 and 2021, the Company granted no performance share units. The actual amount of performance share units vested at the end of each three-year period is measured by the level of achievement of performance goals and can range from 0% to 200% of the award grant. During fiscal 2023, 2022, and 2021, the Company recognized stock-based compensation expense (benefit) associated with the Performance Share Program of $5.6 million, $2.0 million, and $(0.2) million, respectively.